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‘‘blood-based’’ cancers, share many firsts
in the history of cancer research. They
were the first cancers to be treated with
radiation therapy (around 1900), the first
to be clinically tested and treated with
chemotherapy (nitrogen mustard in the
1940s), and, more recently, the first to be
treated with a novel type of therapy called
epigenetic therapy. While companies
have reported impressive earnings for
the first three (and only) epigenetic drugs
approved by the U.S. Food and Drug Ad-
ministration (FDA), all intended for single
agent use in the treatment of either cuta-
neous T cell lymphoma (CTCL; a rare
form of non-Hodgkin’s lymphoma) or
myelodysplastic syndrome (MDS; a pre-
cursor to a type of leukemia known as
acute myelogenous leukemia, or AML),
the hope and expectation is that, once
again, blood is just the beginning. ‘‘We
have been aware of epigenetic defects in
cancer for almost two decades, but it
hasn’t been thought of as a great thera-
peutic direction to go, despite these
agents,’’ says William G. Nelson, an oncol-
ogy researcher at Johns Hopkins Univer-
sity School of Medicine. ‘‘That’s changing
very quickly.’’
Targeting the Epigenome
Unlike the genome, which is kept static
across time, the epigenome is a decidedly
dynamic component of the cell, over
time and among different cell types. The
epigenome encompasses cellular non-
DNA-sequence-based regulatory ele-
ments that control gene expression and
are transmitted from one cellular genera-
tion to the next. Those elements include
methyl modifications of the genome,
covalent modifications of the histone pro-
teins, which are closely associated with
genomic DNA allowing its tight packaging
into chromosomes, and assorted other
chemical changes and entities. The dy-
namic nature of the epigenome makes
biological sense. Utilizing its epigenome
to turn genes on and off in response to
what is happening in its environment,
a cell is able to adapt readily to change
by removing DNA methylation marks or
altering the histone protein in the neces-
sary way. But that same readiness is
a risk, too. It means that things can go
wrong just as quickly as they can go
right—a tumor suppressor gene, for
example, turned off by a misguided cue
could mark the beginning of cancer.
The first evidence that epigenetic ab-
normalities play a role in cancer etiology
was reported by Andy Feinberg and Bert
Vogelstein (Feinberg and Vogelstein,
1983). Prior to that, most biologists were
skeptical of this connection. Today, biolo-
gists are so certain that there is a connec-
tion that they speak of the ‘‘epigenetic
model of cancer,’’ not necessarily in lieu
of but in addition to the mutational model
of cancer (Feinberg et al., 2006), and a
growing number of researchers and com-
panies are becoming involved in epige-
netic drug research and development.
The epigenetic etiology of disease allows
for a new way to treat disease. Instead
of killing damaged cells (i.e., cancer cells),
as conventional chemotherapy does, epi-
genetically active drugs are designed to
reverse the (epigenetic) damage while
keeping cells alive. The goal is to restore
normal states of gene expression by turn-
ing aberrantly silenced genes back on.
There are two main types of epigenetic
drugs: DNA methylation inhibitors and
histone deacetylation inhibitors. Both are
designed to inhibit enzymes that play
key roles in installation of specific epi-
genetic modifications, i.e., epigenetic
programming.
DNA Methyltransferase Inhibitors:
Silence Is Death
The DNA methyltransferases (DNMTs) are
enzymes that transfer methyl groups
(-CH3) to cytosines in DNA during cell divi-
sion. Too many enzymes causes too
much methylation, which usually means
too much gene silencing (e.g., silencing
of tumor suppressor genes) and disease
development. DNMT inhibitors, also
known as demethylating agents, act as
substitutes for cytidine residues during
cell division: they get incorporated into
the DNA in lieu of cytosines, thereby bind-
ing to and blocking DNMTs and depleting
the cell of overly active methylating
enzymes. There are two FDA-approved
demethylating agents: 5-azacytidine
(Vidaza), a derivative of the nucleoside
cytidine; and 5-aza-20-deoxycytidine, or
decitabine (Dacogen), the deoxyribose
analog of 5-azacytidine.
When patients with MDS are adminis-
tered either decitabine or azacytidine,
they gain about an extra year of life.
AML patients appear to live longer lives
as well, when administered either drug,
although that finding is not as well estab-
lished. As Jean-Pierra Issa, a researcher
at the M.D. Anderson Cancer Center
(Houston, TX), notes, ‘‘Other drugs like
classical chemotherapy cytotoxic agents
do not prolong life. I think that this obser-
vation has two very important and very
gratifying implications. One is that we
are affecting people’s lives—not just qual-
ity of life but length of life. But also, these
drugs are different from classical cyto-
toxics, and it is clear that we have intro-
duced a different way of treating cancer.’’
DNMT inhibitors don’t kill. They simply
inflict targeted damage or, rather, reverse
epigenetic damage already done.
Several additional DNMT inhibitor com-
pounds are in development, including the
well-known zebularine (e.g., Marquez
et al., 2005), another derivative of 5-aza-
cytidine, and some lesser known com-
pounds like procainamide, an already
marketed antiarrythmia drug. Hopkins’
Nelson and colleagues have been
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discovered capacity to reverse epigenetic
silencing. ‘‘There’s a little shyness about
the drug in general,’’ says Nelson, ‘‘be-
cause most antiarrythmia drugs have
some proarrythmia risk. It’s not as great
a risk as people think, but it is a worry.’’
Nelson’s team is screening analogs of
procainaimide in search of one (or more)
that would exhibit methyltransferase
inhibition and the propensity for lower
proarrythmia risk.
HDAC Inhibition: Turn It Up!
Ever since it received FDA approval in
October of 2006, Merck’s Zolinza (vorino-
stat), the first and only FDA-approved
histone deacetylase (HDAC) inhibitor,
has generated considerable industry
buzz, boosting interest and investment in
HDAC inhibitor R&D. The HDACs are a
family of 11 enzymes that play a very im-
portant role in regulating gene expression
by removing acetyl groups (CH3CO–) from
histone proteins and shutting down gene
expression. Biologically, deacetylation of
histones causes chromosomal DNA to
wrap more tightly around histones, which
prevents easy access of the transcription
machinery to the genetic information that
needs to be transcribed. Researchers
have reported abnormal HDAC overex-
pression in many different types of cancer
cells. The rationale behind HDAC inhibi-
tion as a cancer therapy is that tumor sup-
pressor genes that have been shut down
by too much HDAC activity will be turned
back on and normal cell function will be
restored. While HDAC inhibitors clearly
inhibit HDAC enzymes, they also inhibit
other aceylation signaling events, making
it difficult to know if the clinical effects
seen with vorinostat or other HDAC inhib-
itors are due to HDAC inhibition, as
planned, or incidental interference with
off-target pathways.
It might be still somewhat of a mystery
why HDAC inhibitors work in the clinic,
but they do work. Vorinostat’s FDA
approval is testament to that. So are
some of the clinical trial results reported
for the other HDAC inhibitors, like panobi-
nostat and romidepsin. Miles Prince, head
of the Haemotology Unit at Peter MacCal-
lum Cancer Centre (Melbourne, Australia),
is involved with clinical trials with both
compounds. Some of the more exciting
results he has seen lately include re-
sponses to single-agent panobinostat
(Novartis’ LBH589) among patients with
Hodgkin’s lymphoma, AML, and MDS
and responses among patients with mye-
loma who have been refractory to borte-
zomib (Millenium’s Velcade, a proteasome
inhibitor), when bortezomib is used in
combination with romidepsin. Romidep-
sin is also in phase II development for
treatment of CTCL and peripheral T cell
lymphomas (PTCL). Both Gloucester
Pharmaceuticals (Gloucester, MA) and
the National Cancer Institute (NCI) are
running trials. According to Prince, the
compound has demonstrated definite
efficacy in these trials, with some patients
entering prolonged remissions of 60
months or more. According to Elizabeth
Faust, vice president of Medical Affairs
at Gloucester, the company plans to file
a new drug application (NDA) for CTCL
by the end of 2008.
Other companies with HDAC inhibitors
in development include MethylGene
(Montreal, Quebec), CuraGen (Branford,
CT), Ortho Biotech (a unit of Johnson &
Johnson, Raritan, NJ), Pharmacyclics
(Sunnyvale, CA), and Syndax (Waltham,
MA). Each is taking its own approach.
For example, according to MethylGene’s
CEO, Donald Corcoran, one of the key
ways that MethylGene differentiates it-
self from the competition is that its lead
HDAC inhibitor compound (MGCD0103)
was rationally designed to target four spe-
cific HDACs involved in specific cancers.
Vorinostat is a paninhibitor and therefore
does not have that same selectivity;
neither does Gloucester’s romidepsin.
From Blood to Body
As to why the focus with DNMT inhibitors
has been on blood-based cancers, says
Issa: ‘‘When the drugs were developed
40 years ago, they were developed as
analogs of the most active leukemia
drug, cytarabine, or ara C. So even before
we knew the mechanism of action of the
drug, people were interested in testing it
in leukemia. So almost all of the early clin-
ical experience with the drug was with
leukemias, and that’s where the respon-
ses were seen at the time.’’
HDAC inhibitors don’t have the same
history, but their focus has been on hema-
tology as well. Again, it is where respon-
ses have been seen. ‘‘People have really
tried with solid tumors, including us,’’
says MethylGene’s Corcoran. ‘‘But at
least as a single agent, hematology is
where the data have been really good.’’
Faust agrees: ‘‘With romidepsin, it really
was an empiric observation. In the can-
cers that were tested, that’s where it had
the most activity.’’ She points out, how-
ever, that most of those tests were with
single agents. The scenario is likely to be
different when results emerge from the
growing number of clinical trials combin-
ing epigenetic drugs with conventional
chemotherapies.
As to whether or not there are any real
biological or chemical differences be-
tween blood-based and solid tissue
cancers, Issa noted just one with deme-
thylating agents: demethylating agents
work only in replicating cells, and the
rate of active cell division is higher in leu-
kemias than in solid tumors. ‘‘So there
are some pharmacological barriers with
solid tumors,’’ he says. But there aren’t
enough to dissuade experts from believ-
ing that a day will come when the results
from combination trials for solid tumors
catch up with some of the positive res-
ponses being seen for the hematological
malignancies. ‘‘We will be at a point in a
few years,’’ says Issa, ‘‘where epigenetic
therapy is incorporated into curative
regimens for many different cancers.’’
REFERENCES
Feinberg, A.P., and Vogelstein, B. (1983). Nature
301, 89–92.
Feinberg, A.P., Ohlsson, R., and Henikoff, S.
(2006). Nat. Rev. Genet. 7, 21–33.
Marquez, V.E., Barchii, J.J., Jr., Kelley, J.A., Rao,
K.V., Agbaria, R., Ben-Kasus, T., Cheng, J.C.,
Yoo, C.B., and Jones, P.A. (2005). Nucleosides
Nucleotides Nucleic Acids 24, 305–318.
Leslie Pray (lpray@nasw.org) is a science writer
based in Holyoke, MA.Chemistry & Biology 15, July 21, 2008 ª2008 Elsevier Ltd All rights reserved 641
